「by」の検索結果
77件：21～25件目を表示
-
that it has received approval for the marketing of “Mytear Lumify” (OTC drug requiring instruction by pharmacist, hereinafter this "Product") from Ministry of Health, Labour and Welfare. Th...
https://www.senju.co.jp/sites/default/files/content_news/2024-08/ENG_20240903.pdf -
ical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter “Senju”) hereby announces the launch of distribution of RET-700 in Japan, effective immediately (medical device a...
https://www.senju.co.jp/sites/default/files/content_news/2024-07/ENG_20240726.pdf -
ical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter “Senju”) hereby announces the launch of distribution of software for dry-eye analysis in Japan as an option of RE...
https://www.senju.co.jp/sites/default/files/content_news/2024-09/ENG_20240906.pdf -
aceutical Co., Ltd. Launch and Distribution of “MIEr for NAVIS” Senju Pharmaceutical Co., Ltd., hereby announces the commercial launch and distribution of “MIEr for NAVIS” in Japan. MIEr for NAVIS can...
https://www.senju.co.jp/sites/default/files/content_news/2024-04/ENG_20240423.pdf -
aceutical Co., Ltd. Launch and Distribution of “MIEr for NAVIS” Senju Pharmaceutical Co., Ltd., hereby announces the commercial launch and distribution of “MIEr for NAVIS” in Japan. MIEr for NAVIS can...
https://www.senju.co.jp/sites/default/files/content_news/2024-04/ENG_20240423_0.pdf